Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Trailing Price-to-Earnings Ratio

News

Movers

Cue reported 2024 fiscal-year earnings on Monday after the market closed.

What&#39;s Going On With Cue Biopharma Shares Tuesday?

Biotech

Earnings

Earnings Misses

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

SLGL

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Intraday Update

ADTH

AIRE

ANNX

ATER

BGNE

BIRD

BTOG

CLOV

CMTL

DLTR

ECDA

EDUC

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HRTX

Kintara Therapeutics, Inc. - Common Stock

KTRA

LICY

LUNA

MINM

MNMD

NAAS

NATR

NCNA

NMRA

PIII

PRTG

RXRX

SIGA

SKIN

SMMT

SURG

SWIN

VERI

VJET

Shares of  Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Press Releases

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Health Care

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma Announces Proposed Public Offering

IPOs

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Adicet Bio

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Annovis Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Avalo Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

InflaRx

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

MDxHealth

Metagenomi

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OS Therapies

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

RenovoRx

Serina Therapeutics

Senti Biosciences

Exicure

Citizens Capital Markets

Stifel

JMP Securities

Piper Sandler

Oppenheimer

Comments

Cue Biopharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell